New hope for nigerian women with aggressive breast cancer: targeted therapy trial underway

NCT ID NCT03879577

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing a combination of two drugs—docetaxel (chemotherapy) and trastuzumab (a targeted therapy)—in 53 Nigerian women with HER2-positive breast cancer. The goal is to see how many women have no cancer left after treatment (called a complete response). The study also tracks side effects and how long women stay cancer-free. All participants are treated at a single center in Nigeria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Docetaxel and trastuzumab (Herceptin), with possible FEC, tamoxifen, or letrozole
What this could lead to
If successful, this could show that a standard chemotherapy plus targeted therapy regimen works well in Nigerian women with HER2-positive breast cancer, potentially improving treatment options in this population.
What could go wrong
This is a small, single-arm Phase 2 study with only 53 participants, so results may not apply broadly. Side effects from chemotherapy and trastuzumab can be serious, including heart problems and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University College Hospital, Ibadan, Nigeria

    Ibadan, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.